Effects of endotoxin and influence of cyclooxygenase-2 on ß-adrenergic mediated relaxation in isolated equine digital artery.

The effects of endotoxin on ß-adrenergic-mediated relaxation were investigated in the equine digital artery (EDA). Possible involvement of cyclooxygenase-2 (COX-2) in endotoxin-induced effects and basal EDA ß-adrenoceptor functionality was also evaluated. Endothelium-intact (e(+)) and/or -denuded (e(-)) EDA rings were incubated overnight with lipopolysaccharide (LPS), LPS+NS398 (selective COX-2 inhibitor) or NS398 alone. Vessel rings were then mounted in organ baths and relaxant responses to isoproterenol (ISOP) recorded on U44069-induced pre-contraction. Response to ISOP was further evaluated in either incubated or freshly isolated (e(-)) rings acutely exposed to NS398. Fresh and incubated (e(-)) EDAs were also analysed for COX-2 expression by Western blotting. LPS caused endothelium-dependent enhancement of ß-adrenergic mediated relaxation. NS398 did not reverse endotoxin effects, suggesting that COX-2 did not have a mediating role. In the absence of LPS, NS398 significantly increased ISOP-induced relaxation. This finding, together with immunoblot detection of COX-2 in both fresh and incubated (e(-)) vessels, revealed the existence of a constitutive COX-2 exerting tonic inhibitory modulation on EDA ß-adrenergic-mediated relaxation. The results support the possible role of endotoxin in the vascular disturbances associated with equine laminitis. Moreover, the involvement of COX-2 in the physiological regulation of EDA tone warrants further clinical investigation into the efficacy and safety of selective COX-2 inhibitors on digital circulation in horses.

A clonal cell line (BME-UV1) as a possible model to study bovine mammary epithelial metabolism: metabolism and cytotoxicity of aflatoxin B1.

Despite the toxicological risks to which humans and animals are exposed due to the transfer of toxic xenobiotic metabolites into milk of domestic animals, studies on the metabolizing mechanisms occurring in ruminant mammary gland are totally lacking. To investigate the possible biotransformation capabilities of a bovine mammary epithelial cell line (BME-UV1), monolayers were exposed to aflatoxin B1 (AFB1--1.0-8.0 microM). Starting from 4 h of exposure, the hydroxylate metabolite aflatoxin M1 (AFM1) was detected in media by high performance liquid chromatography. AFM1 concentration increased linearly with time for 36-48 h and the percent biotransformation of AFB1 (2-4 microM) at 48 h was about 12-14%. Parallel cytotoxicity assays (neutral red uptake-NRU and MTT assays) were performed to investigate the possible interference of AFB1 cytotoxicity with cellular metabolism. MTT assay (from 24 h of cell exposure) and NRU assay (from 16 h of cell exposure) showed time-dependent and time/concentration-dependent decrease of cell viability, respectively, and the former assay being more successful at revealing cytotoxic effects (NRU: CC50 at 48 h = 12.00 +/- 2.66 microM; MTT: CC50 at 72 h = 20.42 +/- 7.30 microM). The results suggest that BME-UV1 cells express metabolizing enzymes having catalytic activity, thus representing a potential in vitro model for studying biotransformation in bovine mammary gland.

Investigation of the metabolic activity of a bovine mammary epithelial cell line (BME-UV1).

The metabolic activity of a mammary epithelial cell line (BME-UV1) was evaluated on monolayers exposed, in serum free medium, to different concentrations (2-4-8 muM) of aflatoxin B1 (AFB1), a mycotoxin eliminated into milk especially as hydroxylated metabolite aflatoxin M1 (AFM1). After 4, 8, 12, 24 h of treatment, a dose and time dependent production of AFM1 has been detected. As the enzymes involved in the hydroxylation of AFB1 in bovine hepatocytes are mainly CYP1A and CYP3A, the results suggest that BME-UV1 express CYP450 isoenzymes which metabolize AFB1 thus representing a potential model for the investigation of the metabolic activity of bovine mammary epithelial tissue.

Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.

The pharmacokinetics and mammary excretion of imidocarb dipropionate, a therapeutic/prophylactic agent against a variety of tick-borne hemoparasitic diseases in domestic animals, have been investigated in sheep and goats. A commercial formulation of imidocarb di-propionate was injected i.m. at a single dose of 3 mg/kg of body weight in 7 mature lactating ewes and 8 lactating does in good health. Blood samples were collected for 48 h after administration and milk samples were collected every 12 h for 10 d. A weak cation-exchange solid-phase procedure was used to remove imidocarb from plasma. A hexane/isoamyl alcohol liquid-liquid procedure was adopted to extract the drug from the milk of sheep. The same method was used for goat milk after exposing the matrices to enzymatic digestion. The extracted samples were analyzed by HPLC. The i.m. disposition kinetics of imidocarb in the 2 species showed significant differences in the rate of elimination (0.0075 +/- 0.002 and 0.025 +/- 0.004 L/h in sheep and goats, respectively), being faster in ewes than in does. Nevertheless, a smaller area under the concentration-time curve (12.21 +/- 0.76 and 9.49 +/- 0.54 microg/mL per h in sheep and goats, respectively), a larger volume of distribution (4.18 +/- 0.44 and 7.68 +/- 0.57 L/kg in sheep and goats, respectively), and a longer mean residence time (9.07 +/- 0.77 and 14.75 +/- 2.20 h in sheep and goats, respectively) were found in goats, suggesting a more rapid and effective drug storage in tissues during the first 48 h after the injection. The concentrations of imidocarb in milk of both species were higher than in plasma. However, a fast passage through the blood-milk barrier and a high storage of imidocarb were observed in the milk of ewes, whereas the drug concentrations were not as high nor was the extent of drug penetration from blood to milk as great in the milk of goats (AUC(milk 0-48)/AUC(plasma 0-48) = 2.5 +/- 0.45 and 1.26 +/- 0.27 in sheep and goat, respectively). Despite the differences in pharmacokinetic behavior, and considering the sensitivity of pathogens to imidocarb, the same dosage regimen can be used for clinical efficacy against Babesia spp. infection in both species. In contrast, the differences in depletion of imidocarb residue in milk and the large variability in mammary drug elimination found in goats suggests that great care should be taken in defining the withdrawal time in small ruminant dairy species.

Pharmacokinetics of imidocarb dipropionate in horses after intramuscular administration.

The objective of this study was to determine the pharmacokinetic behaviour of imidocarb in horses following a single i.m. injection at the dose commonly administered to treat Babesia caballi infections or to prevent babesiosis. Eight horses were injected i.m. with a single dose of 2.4 mg imidocarb dipropionate/kg bwt and blood, faecal, urine and milk samples were collected. For imidocarb determination, a high-performance liquid chromatographic method (HPLC) was used after weak cation-exchange solid phase, or liquid-liquid, extraction procedures. Twelve hours after treatment, no detectable plasma concentrations were recorded in any of the treated animals. The distribution and elimination patterns of the drug suggested that it is quickly sequestrated in some storage tissues and remains in the body for a long time. Its prolonged presence in the body may confer a reservoir effect to imidocarb in some tissues, therefore making it undetectable in the plasma of animals but sufficient to produce its described therapeutic and prophylactic activities.

Identification of functional alpha-adrenoceptor subtypes in the bovine female genital tract during different phases of the oestrous cycle.

The concentration and functionality of the alpha-adrenoceptor (alpha-AR) subtypes in the genital tract of cyclic heifers were investigated. In each tissue sample, a single class of alpha1-ARs was observed, whereas two distinct classes of alpha2-ARs were discriminated: low-affinity (LA) and high-affinity (HA) alpha2-ARs. Statistical analysis showed the presence of significantly (p < 0.05) higher concentrations of all alpha-AR subtypes in the follicle than in the corpus luteum. No significant differences were found in the ovary or myometrium between the luteal and follicular phases. In the ovary, the density of alpha1-ARs was significantly (p < 0.05) higher than that of alpha2-ARs. By contrast, there were significantly (p < 0.05) more alpha2-ARs than alpha1-ARs in the myometrium. As far as alpha2-ARs are concerned, LA alpha2-ARs were significantly (p<0.05) higher than HA alpha2-ARs in all tested tissues. Competition studies suggested that the rank order of potency of antagonists for alpha1-ARs was prazosin > phentolamine > yohimbine, whereas for alpha2-ARs the order of potency was yohimbine > or = phentolamine>prazosin. Functional assays performed on myometrium showed that noradrenaline, phenylephrine and clonidine elicited concentration-dependent contractions only in dioestrus and pro-oestrus preparations and that clonidine was more effective than phenylephrine as a contractile agent. It appeared that there were no significant modifications in alpha-AR affinity or concentration during the different stages of bovine oestrous cycle, whereas the uterine spontaneous activity and the responsiveness to alpha-adrenergic stimulation was strongly influenced by hormonal levels. The modifications of uterine contractility observed during the oestrous cycle may be related to modifications induced in the transductional mechanisms of alpha-ARs.

Determination of dexamethasone in milk of dairy cows by immuno-enzymatic assay.

Eight lactating cows received 3 im injections at 24 h intervals of a commercial formulation containing dexamethasone. Each treatment provided 25 microg/kg bw/d of dexamethasone acetate, equivalent to 22.6 mg of dexamethasone. Milk samples were obtained before treatment (5 d), during the treatment period, and for up to 22 milking after the last injection. The concentrations of dexamethasone in the milk samples were determined by a commercial competitive immunoenzymatic assay for corticosteroids (detection limit 0.15 ng dexamethasone/ml). The conventional therapeutic dose of dexamethasone acetate caused milk drug concentrations exceeding the tolerated maximum residue limit (0.3 mg/kg). A withdrawal time of 3-3.5 d for dexamethasone in milk provided sufficient protection for consumer health. The commercial enzyme immunoassay kit employed in this study was sufficiently sensitive, easy to use, and appropriate to monitor the use of dexamethasone in lactating animals.

Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.

The disposition of a combination of antimony (Sbv) (12.8 mg/kg) and aminosidine (AM) (10 mg/kg) in 10 healthy Beagle dogs after multiple subcutaneous injections is described. Sbvplasma concentrations were determined by atomic absorption spectrometry, and AM by ion-pair liquid chromatography, using a fluorimetric detector. Sbvreached Cmaxat 60 min, and for about 1 h plasma levels were homogeneously stabilized between 10.78 and 11.76 microgram/mL; by 12 h, Sbvplasma concentrations were close to the detection limit (0.3 microgram/mL). AM Cmaxvalues were recorded after 1 h (30.6+/-3.11 microgram/mL, mean +/- SD), and plasma levels reached values close to the detection limit (0.15 microgram/mL) between 7 and 8 h after injection. Sbvkinetic parameters did not appear modified by the presence of AM. Moreover, repeated injections of the combination did not modify the kinetic behaviour of the two drugs and did not alter the renal function of the animals. The superimposition analysis of the Sbvdata suggests that a twice daily injection of the metal at a dose of 12.8 mg/kg would be sufficient to maintain inhibitory Sbvconcentrations similar to those recorded in humans.

Pharmacokinetics and dosing regimen of aminosidine in the dog.

The kinetic behaviour of the aminoglycoside aminosidine, given at 15 mg/kg intravenously, intramuscularly and subcutaneously, was studied in 5 dogs to determine the appropriate dosage schedule. The pharmacokinetic behaviour of aminosidine in dogs was similar to that in other species, except that it was eliminated more slowly (beta = 0.007 +/- 0.0003 min-1). Intramuscular and subcutaneous administration produced peak serum concentrations (Cmax[im] = 32 +/- 6.4 micrograms/ml; Cmax[ac] = 36 +/- 3.4 micrograms/ml) and times to peak concentration (Tmax = 60 min for both) that did not differ significantly; and neither compartmental nor non-compartmental analysis revealed any significant differences between any of the kinetic parameters obtained for these two extravenous routes of administration. Comparison of these results with previously published data suggests that aminosidine given once daily at 15 mg/kg would be as effective all, and safer than, the two or three daily administrations commonly employed in dogs.

Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.

The pharmacokinetic behaviour of aminosidine (15 mg kg-1) and antimony (25.65 mg kg-1 as N-methylglucamine antimoniate), administered subcutaneously either separately or together was studied on four dogs. The results demonstrated that antimony (Sb) did not significantly modify the kinetics of aminosidine (AM) but that the kinetic behaviour of the metal was markedly influenced by the antibiotic, as shown by the differences in mean residence time (MRT), elimination rate constant (Kel) and area under the curve (AUC) with and without the antibiotic (MRT[Sb] = 243.8 +/- 29.5 minutes, MRT[Sb+AM] = 1067.9 +/- 199.2 minutes; Kel[Sb] = 0.008 +/- 0.001 min-1, Kel[Sb+AM] = 0.0015 +/- 0.0003 min-1; AUC[Sb] = 21,024.6 +/- 4448.5 micrograms min ml-1, AUC[Sb+AM] = 130,478.5 +/- 30,481.7 micrograms min ml-1). The persistence of high serum concentrations of antimony when it was administered with aminosidine suggests that the therapeutic doses commonly used should be reduced and that the interval between administration should be increased to avoid the metal reaching toxic concentrations.

Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.

The pharmacokinetic profile of antimony in dogs was defined by administering it intravenously, intramuscularly and subcutaneously as N-methylglucamine antimoniate at a dose of about 25.65 mg of antimony kg-1 bodyweight. The results showed a different half-life for the three routes of administration: 20.5, 42.1 and 121.6 minutes for the intravenous, intramuscular and subcutaneous routes, respectively; peak time values (Tmax) were also different for the intramuscular (90 to 120 minutes) and subcutaneous (210 to 240 minutes) injection. The apparent bioavailability of antimony was > 100 per cent for the intramuscular and 100 per cent for the subcutaneous routes. The data obtained showed a relevant difference in the behaviour of the drug in the dog in comparison to that in humans.

Dipsogenic-like and behavioural effects of bombesin administered intracerebroventricularly to sheep.

Bombesin administered intracerebroventricularly both by bolus injection (3.0, 6.0, 12.5, 25.0 and 50.0 ng kg-1) and slow infusion (0.4, 0.8 and 1.6 ng kg-1 min-1 for 30 min) potently and promptly stimulated water intake in sheep. This effect was dose dependent and bombesin was slightly more potent than angiotensin II (on a molar basis); both caused behavioural alterations (scratching and licking) in treated animals. Intravenous bolus injections of bombesin at doses up to 2500 ng kg-1 did not elicit either dipsogenic-like or behavioural effects, unlike angiotensin II. The receptor antagonist of angiotensin II, saralasin, provoked drinking in sheep at doses of 18.7, 37.5 and 75.0 ng kg-1 by intracerebroventricular bolus injection. These results surprisingly revealed that bombesin, a potent inhibitor of water intake in other mammals (rats and pigs), exerted in sheep dipsogenic-like effects similar to those in pigeons and ducks.

Possible mechanisms of action of caerulein on intestinal motility of sheep.

The authors report the stimulatory effects provoked by caerulein on caecum and colon motilities in sheep which are quite opposite to those exerted by the same peptide on the forestomach and abomasal sections. By means of various pharmacological tools these effects are suggested to be attributable to a direct effect of caerulein on the smooth muscle of these viscera through the involvement of receptors different from those ones on which CCK may be antagonizable by proglumide or cGMP pretreatments.

The effects of caerulein on exocrine pancreatic secretion in pigs.

Caerulein administered to anaesthetized pigs by slow i.v. infusions at doses of 0.5, 1.0 and 2.0 ng kg-1 min-1 for 30 min, stimulated pancreatic juice production, increased the protein content of the juice and enhanced its amylolytic, lipolytic and proteolytic activities. In a single experiment, an i.v. infusion of secretin (0.001 U kg-1 min-1) lasting through the whole experimental time, provoked potentiation of the caerulein stimulatory effects on pancreatic juice production, protein content and amylolytic activity.

Effects of Caerulein on exocrine pancreatic secretion in sheep.

caerulein administered by slow intravenous infusion at increasing dosage rates (0.1, 1.0, 5.0 and 10.0 ng/kg/min X 30 min) stimulated pancreatic juice production in sheep as well as the protein content, the amylolytic, the lipolytic and proteolytic activities of pancreatic juice samples collected at 30 min intervals. A long lasting (300 min) infusion of a high dose of Caerulein by subcutaneous route elicited stimulatory effects with reduced intensities, slower onsets but more sustained durations than those produced by the same dose level administered intravenously.

The effects of eledoisin on intestinal smooth muscle of ruminants.

The effects of eledoisin on the intestinal smooth muscle of ruminants are reported. The results obtained on isolated in vitro preparations from cattle suggest a direct effect of the peptide on the smooth muscle of the different intestinal sections examined. The observations made during in vivo experiments on sheep suggest that eledoisin produces its effects by also affecting the autonomic nerve supply to the intestine of these animals.